Biomarker discovery by comprehensive phenotyping for autoimmune diseases

There is a well-recognized but unmet need for biological markers to characterize disease type, status, progression, and response to therapy in autoimmune diseases. We are developing and applying an integrated bioanalytical platform and clinical research program to facilitate comprehensive differenti...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 111(2004), 2 vom: 14. Mai, Seite 186-95
1. Verfasser: Kantor, Aaron B (VerfasserIn)
Weitere Verfasser: Wang, Weixun, Lin, Hua, Govindarajan, Harini, Anderle, Markus, Perrone, Andrea, Becker, Christopher
Format: Aufsatz
Sprache:English
Veröffentlicht: 2004
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, U.S. Gov't, Non-P.H.S. Biomarkers
LEADER 01000naa a22002652 4500
001 NLM148283802
003 DE-627
005 20231223045232.0
007 tu
008 231223s2004 xx ||||| 00| ||eng c
028 5 2 |a pubmed24n0494.xml 
035 |a (DE-627)NLM148283802 
035 |a (NLM)15137951 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Kantor, Aaron B  |e verfasserin  |4 aut 
245 1 0 |a Biomarker discovery by comprehensive phenotyping for autoimmune diseases 
264 1 |c 2004 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 29.06.2004 
500 |a Date Revised 19.11.2015 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a There is a well-recognized but unmet need for biological markers to characterize disease type, status, progression, and response to therapy in autoimmune diseases. We are developing and applying an integrated bioanalytical platform and clinical research program to facilitate comprehensive differential phenotyping of patient samples and enable the discovery of biomarkers. Our measurement platform includes microvolume laser scanning cytometry for the quantification of hundreds of cellular parameters in whole blood and other samples, liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry for the quantification of proteins and low molecular weight biomolecules in serum and other fluids or tissues, and specific immunoassays for the quantification of trace proteins in serum. We describe the technologies and discuss initial applications to the analysis of subjects with rheumatoid arthritis (RA) and healthy controls 
650 4 |a Journal Article 
650 4 |a Research Support, U.S. Gov't, Non-P.H.S. 
650 7 |a Biomarkers  |2 NLM 
700 1 |a Wang, Weixun  |e verfasserin  |4 aut 
700 1 |a Lin, Hua  |e verfasserin  |4 aut 
700 1 |a Govindarajan, Harini  |e verfasserin  |4 aut 
700 1 |a Anderle, Markus  |e verfasserin  |4 aut 
700 1 |a Perrone, Andrea  |e verfasserin  |4 aut 
700 1 |a Becker, Christopher  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 111(2004), 2 vom: 14. Mai, Seite 186-95  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:111  |g year:2004  |g number:2  |g day:14  |g month:05  |g pages:186-95 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 111  |j 2004  |e 2  |b 14  |c 05  |h 186-95